# A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients

> **NCT02204722** · PHASE4 · TERMINATED · sponsor: **Dong-A ST Co., Ltd.** · enrollment: 55 (actual)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** 600mg/day of Imatinib
- **DRUG:** 400mg/day of Imatinib

## Key facts

- **NCT ID:** NCT02204722
- **Lead sponsor:** Dong-A ST Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-10-13
- **Primary completion:** 2017-05-23
- **Final completion:** 2018-01-09
- **Target enrollment:** 55 (ACTUAL)
- **Why stopped:** Sponsor's decision to halt the study.
- **Last updated:** 2018-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02204722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02204722, "A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02204722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*